To further explore the function of MAP3K1 mutation on regulating tumor immune microenvironment, we performed the cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) analysis and discovered that tumors with MAP3K1 mutation had a lower abundance of CD8+ T cells, the main immune effector cells for antitumor immunity, compared with tumors without MAP3K1 mutation (Figure 1J). This evidence concerns the gene CD8A and neoplasm.